United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$353.00 USD
+1.67 (0.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $353.03 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Income Statements
Fiscal Year end for United Therapeutics Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,328 | 1,936 | 1,686 | 1,483 | 1,449 |
Cost Of Goods | 258 | 152 | 123 | 108 | 118 |
Gross Profit | 2,070 | 1,785 | 1,563 | 1,375 | 1,331 |
Selling & Adminstrative & Depr. & Amort Expenses | 885 | 805 | 1,007 | 782 | 1,519 |
Income After Depreciation & Amortization | 1,185 | 980 | 556 | 594 | -188 |
Non-Operating Income | 149 | 3 | 57 | 69 | 67 |
Interest Expense | 59 | 32 | 19 | 24 | 44 |
Pretax Income | 1,274 | 951 | 594 | 639 | -165 |
Income Taxes | 290 | 223 | 118 | 124 | -61 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 985 | 727 | 476 | 515 | -105 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 985 | 727 | 476 | 515 | -105 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,238 | 1,031 | 606 | 644 | -142 |
Depreciation & Amortization (Cash Flow) | 53 | 51 | 50 | 50 | 46 |
Income After Depreciation & Amortization | 1,185 | 980 | 556 | 594 | -188 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 49.70 | 48.50 | 47.30 | 44.60 | 43.80 |
Diluted EPS Before Non-Recurring Items | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 |
Diluted Net EPS (GAAP) | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 |
Fiscal Year end for United Therapeutics Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 714.90 | 677.70 | 614.70 | 609.40 | 596.50 |
Cost Of Goods | 77.80 | 72.90 | 71.00 | 70.10 | 64.10 |
Gross Profit | 637.10 | 604.80 | 543.70 | 539.30 | 532.40 |
SG&A, R&D, and Dept/Amort Expenses | 317.20 | 248.50 | 283.60 | 212.30 | 219.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 319.90 | 356.30 | 260.10 | 327.00 | 313.40 |
Non-Operating Income | 47.00 | 55.60 | 50.40 | 40.40 | 36.60 |
Interest Expense | 11.60 | 13.30 | 15.10 | 15.60 | 14.80 |
Pretax Income | 355.30 | 398.60 | 295.40 | 351.80 | 335.20 |
Income Taxes | 77.20 | 92.00 | 78.30 | 84.20 | 76.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 278.10 | 306.60 | 217.10 | 267.60 | 259.20 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 278.10 | 306.60 | 217.10 | 267.60 | 259.20 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 47.50 | 49.70 | 49.80 | 49.70 | 49.50 |
Diluted EPS Before Non-Recurring Items | 5.85 | 6.17 | 4.36 | 5.38 | 5.24 |
Diluted Net EPS (GAAP) | 5.85 | 6.17 | 4.33 | 5.38 | 5.24 |